OKYO Pharma Stock
OKYO Pharma Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Robert J. Dempsey
- Employees
- 5
- Market cap
- $74 M
- IPO
- 17/05/2022
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye…
OKYO Pharma stock: price history
1D
-1.4%
1W
-0.7%
1M
+6.0%
6M
-15.1%
YTD
-31.9%
1Y
-33.2%
2Y
+34.3%
5Y
–
10Y
–
Next earnings date
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
~18% weaker price swings than usual
Ask the agents about OKYO Pharma
Analyst assessment of OKYO Pharma
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 13/07/2026
OKYO Pharma stock metrics
P/E
-5.9
P/B
4.27
EV/EBITDA
-6.46
RETURN ON EQUITY
-51.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
53.2%
FLOAT SHARES
27,935,377
AVG. DAILY VOLUME (30D)
71,699
Insider transactions (SEC)
Patil Rajkumar V.
JACOB GARY S
CERRONE GABRIELE M
Dempsey Robert John
BRANCACCIO JOHN P
Comparable stocks
Frequently asked questions about OKYO Pharma stock
What does OKYO Pharma do?
OKYO Pharma Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Robert J. Dempsey, the company employs around 5 people.
The IPO was on 17/05/2022; the stock trades on NASDAQ under the ticker OKYO.
What do analysts say about OKYO Pharma stock?
2 analysts rate the stock, the consensus is Buy (as of 13/07/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does OKYO Pharma report next?
The next earnings date is 02/12/2026.
Around past earnings, price swings were roughly -18% stronger than usual.
Does OKYO Pharma pay a dividend?
No, OKYO Pharma currently does not pay a dividend.
Which stocks are comparable to OKYO Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get OKYO Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess OKYO Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.